|
Sign In to gain access to subscriptions and/or personal tools.
|
Prognostic determinants in lupus nephritis: a long-term clinicopathologic study
JV Donadio, JR
Division of Nephrology and Internal Medicine, Department of Biostatistics, Mayo Clinic and Mayo Foundation, Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, USA
GM Hart
Division of Nephrology and Internal Medicine, Department of Biostatistics, Mayo Clinic and Mayo Foundation, Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, USA
EJ Bergstralh
Division of Nephrology and Internal Medicine, Department of Biostatistics, Mayo Clinic and Mayo Foundation, Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, USA
KE Holley
Division of Nephrology and Internal Medicine, Department of Biostatistics, Mayo Clinic and Mayo Foundation, Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, USA
Over the past 50 years, survival has improved in patients with systemic lupus erythematosus and associated nephritis. Yet, there are few long-term outcome studies in patients with well-defined nephropathy. We examinbed the outcome of 439 patients with lupus nephritis who were seen at the Mayo Clinic between 1964 and 1986 in whom renal biopsies were assessed using the World Health Organization (WHO) classification. There were 341 women and 98 men (mean ± s.d., age 33.5 ± 14 years); 200 (46%) patients were hypertensive and 249 (57%) had impaired renal function at renal biopsy. All WHO morphologic classes were represented and 339 (77%) patients had class III, IV and V (the more severe forms of nephritis). Follow-up averaged 10.2 years per patient. At last contact, 286 (65%) patients were alive and 153 (35%) were dead. Overall patient survival was 80%, 69% and 53% at 5, 10 and 20 years after biopsy that was significantly worse than expected survival (P < 0.001). Ten-year cumulative patient survival improved comparing earlier to more recent time spans: 64% in 231 patients seen during 1964-75; 76% in 2089 patients studied during 1976-86 (P = 0.03). Survival free of renal failure was 83%, 74% and 64% at 5, 10 and 20 years, and survival was unfavorably influenced by progressive WHO class, hypertension, impaired renal function, nephrotic range proteinuria, hypoalbuminemia and anemia. Multivariate analysis found impaired renal function, increased urine protein, anemia and younger age to be independent predictors of renal failure. WHO class was not a significant predictor when adjusted for these four factors. Cardiovascular events accounted for 48% of the known deaths and were equally distributed across all WHO classes, followed by infections, renal failure, malignancy, respiratory failure and gastrointestinal bleeding. Severe nephritis, nephrotic syndrome, hypertension and anemia remain strong predictors of a poor renal outcome. Prospective randomized studies stratifying for these factors are needed to find optimal immunosuppressive regimens to improve renal survival.
Key Words: lupus nephritis • prognosis • pathology
Lupus, Vol. 4, No. 2,
109-115 (1995)
DOI: 10.1177/096120339500400206
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P Hari, A Bagga, P Mahajan, and A Dinda
Outcome of lupus nephritis in Indian children
Lupus,
April 1, 2009;
18(4):
348 - 354.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. A. Austin III, G. G. Illei, M. J. Braun, and J. E. Balow
Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy
J. Am. Soc. Nephrol.,
April 1, 2009;
20(4):
901 - 911.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Venegas-Pont, J. C. Sartori-Valinotti, C. Maric, L. C. Racusen, P. H. Glover, G. R. McLemore Jr., A. V. Jones, J. F. Reckelhoff, and M. J. Ryan
Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus
Am J Physiol Regulatory Integrative Comp Physiol,
April 1, 2009;
296(4):
R1282 - R1289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.O. Sun, W.X. Hu, H.L. Xie, H.T. Zhang, H.P. Chen, C.H. Zeng, Z.H. Liu, and L.S. Li
Long-term outcome of Chinese patients with membranous lupus nephropathy
Lupus,
January 1, 2008;
17(1):
56 - 61.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. H. Cramer II, M. Mills, R. P. Valentini, W. E. Smoyer, H. Haftel, and P. D. Brophy
Clinical presentation and outcome in a cohort of paediatric patients with membranous lupus nephritis
Nephrol. Dial. Transplant.,
December 1, 2007;
22(12):
3495 - 3500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Moroni, S. Quaglini, B. Gallelli, G. Banfi, P. Messa, and C. Ponticelli
The long-term outcome of 93 patients with proliferative lupus nephritis
Nephrol. Dial. Transplant.,
September 1, 2007;
22(9):
2531 - 2539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Alperovich, I Rama, N Lloberas, M Franquesa, R Poveda, M Goma, I Herrero-Fresneda, J M Cruzado, N Bolanos, M Carrera, et al.
New immunosuppresor strategies in the treatment of murine lupus nephritis
Lupus,
January 1, 2007;
16(1):
18 - 24.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A Mak, C C Mok, W P Chu, C H To, S N Wong, and T C Au
Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups
Lupus,
January 1, 2007;
16(1):
28 - 34.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C E. Barber, L Geldenhuys, and J G Hanly
Sustained remission of lupus nephritis
Lupus,
February 1, 2006;
15(2):
94 - 101.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K C Tse, F K Li, S Tang, C S-O Tang, K N Lai, and T M Chan
Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria
Lupus,
December 1, 2005;
14(12):
947 - 952.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T M Chan, K C Tse, C S. Tang, K N Lai, and F K Li
Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine
Lupus,
April 1, 2005;
14(4):
265 - 272.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T.-M. Chan, K.-C. Tse, C. S.-O. Tang, M.-Y. Mok, F.-K. Li, and for the Hong Kong Nephrology Study Group
Long-Term Study of Mycophenolate Mofetil as Continuous Induction and Maintenance Treatment for Diffuse Proliferative Lupus Nephritis
J. Am. Soc. Nephrol.,
April 1, 2005;
16(4):
1076 - 1084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T M Chan
Lupus nephritis: induction therapy
Lupus,
March 1, 2005;
14(3_suppl):
s27 - s32.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C C Mok
Prognostic factors in lupus nephritis
Lupus,
January 1, 2005;
14(1):
39 - 44.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H A Austin and G G Illei
Membranous lupus nephritis
Lupus,
January 1, 2005;
14(1):
65 - 71.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. Chan
Lupus nephritis: induction therapy
Lupus,
January 1, 2005;
14(1_suppl):
s27 - s32.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M A Dooley, C Aranow, and E M Ginzler
Review of ACR renal criteria in systemic lupus erythematosus
Lupus,
November 1, 2004;
13(11):
857 - 860.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D Jayne and A Tyndall
Autologous stem cell transplantation for systemic lupus erythematosus
Lupus,
May 1, 2004;
13(5):
359 - 365.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Jayne, J. Passweg, A. Marmont, D. Farge, X. Zhao, R. Arnold, F. Hiepe, I. Lisukov, M. Musso, J. Ou-Yang, et al.
Autologous stem cell transplantation for systemic lupus erythematosus
Lupus,
March 1, 2004;
13(3):
168 - 176.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. G. Barr, S. Seliger, G. B. Appel, R. Zuniga, V. D'Agati, J. Salmon, and J. Radhakrishnan
Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity
Nephrol. Dial. Transplant.,
October 1, 2003;
18(10):
2039 - 2046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Bujan, J Ordi-Ros, J Paredes, M Mauri, L Matas, J Cortes, and M Vilardell
Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients
Ann Rheum Dis,
September 1, 2003;
62(9):
859 - 865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.J. Howie, N. Turhan, and D. Adu
Powerful morphometric indicator of prognosis in lupus nephritis
QJM,
June 1, 2003;
96(6):
411 - 420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Cortes-Herandez, J Ordi-Ros, M Labrador, A Segarra, J L Tovar, E Balada, and M Vilardell-Tarres
Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone
Lupus,
April 1, 2003;
12(4):
287 - 296.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Zabaleta-Lanz, R E Vargas-Arenas, F Tapanes, I Daboin, J A. Pinto, and N E Bianco
Silent nephritis in systemic lupus erythematosus
Lupus,
January 1, 2003;
12(1):
26 - 30.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. R. MacGowan, S. Ellis, M. Griffiths, and D. A. Isenberg
Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999
Rheumatology,
September 1, 2002;
41(9):
981 - 987.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Moroni, G. C. Greloni, and C. Ponticelli
Late recurrence of lupus nephritis after long-term clinical remission
Nephrol. Dial. Transplant.,
April 1, 2001;
16(4):
849 - 852.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Hallegua, D J Wallace, A L Metzger, R Z Rinaldi, and J R Klinenberg
Cyclosporine for lupus membranous nephritis:experience with ten patients and review of the literature
Lupus,
May 1, 2000;
9(4):
241 - 251.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. C. Mok, K. W. Lee, C. T. K. Ho, C. S. Lau, and R. W. S. Wong
A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population
Rheumatology,
April 1, 2000;
39(4):
399 - 406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bono, J.S. Cameron, and J.A. Hicks
The very long-term prognosis and complications of lupus nephritis and its treatment
QJM,
April 1, 1999;
92(4):
211 - 218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. CAMERON
Lupus Nephritis
J. Am. Soc. Nephrol.,
February 1, 1999;
10(2):
413 - 424.
[Full Text]
|
|
|
|
|
|
|
H A Austin
Clinical evaluation and monitoring of lupus kidney disease
Lupus,
November 1, 1998;
7(9):
618 - 621.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M A Dooley and R J Falk
Immunosuppressive therapy of lupus nephritis
Lupus,
November 1, 1998;
7(9):
630 - 634.
[Abstract]
[PDF]
|
|
|
|
|
